Trial Profile
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 28 Apr 2022
Price :
$35
*
At a glance
- Drugs Tesevatinib (Primary) ; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions
- Sponsors Kadmon Corporation
- 28 Feb 2022 The primary endpoint has been changed from Safety: Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability and MTD to Safety and Tolerability: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) by Severity and/or Relationship to Tesevatinib and Safety and Tolerability: Percentage of Subjects With Serious Adverse Event (SAE) Related to Tesevatinib, according to ClinicalTrials.gov record.
- 28 Aug 2017 Status changed from active, no longer recruiting to discontinued.
- 29 Nov 2016 Planned primary completion date changed from 30 Sep 2016 to 1 Dec 2016.